Stockscreener 앱 받기
92.14
2.75%
-2.515
전일 마감가:
$94.66
열려 있는:
$93
하루 거래량:
836.47K
Relative Volume:
0.43
시가총액:
$18.34B
수익:
$4.81B
순이익/손실:
$1.19B
주가수익비율:
15.46
EPS:
5.961
순현금흐름:
$1.17B
1주 성능:
-5.41%
1개월 성능:
-8.63%
6개월 성능:
+10.78%
1년 성능:
+35.92%
1일 변동 폭
$91.70
$93.45
1주일 범위
$91.70
$97.86
52주 변동 폭
$53.56
$112.29
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
92.15 | 18.84B | 4.81B | 1.19B | 1.17B | 5.961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.58 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.38 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.93 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.56 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
286.72 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-05 | 개시 | H.C. Wainwright | Buy |
| 2026-01-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
WINTON GROUP Ltd Acquires 213,557 Shares of Incyte Corporation $INCY - MarketBeat
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts - Benzinga
INCY: Today's Analyst Rating Update by HC Wainwright & Co. | INC - GuruFocus
Incyte wins EC approval of Zynyz for SCAC - The Pharma Letter
Meiji Yasuda Asset Management Co Ltd. Has $2.34 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Corporation $INCY Stake Reduced by Vinva Investment Management Ltd - MarketBeat
Assessing Incyte (INCY) Valuation After EC Approval Of Zynyz For Advanced Anal Cancer - simplywall.st
FDA Declines New Indication for Incyte's (INCY) Zynyz Due to Manufacturing Issues - GuruFocus
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant - Seeking Alpha
Incyte (INCY) Gains EC Approval for Combination Therapy with Zyn - GuruFocus
Incyte Corporation (INCY) Receives FDA Complete Response Letter for Zynyz® sBLA - GuruFocus
FDA issues complete response letter for Incyte’s Zynyz application in lung cancer - Investing.com
Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals - Yahoo Finance
FDA issues CRL for Incyte sBLA for Zynyz in NSCLC over third-party facility inspection - TradingView
(retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
Incyte Momentum Builds With Strong Cash Flows Ahead Of Key Conference - Yahoo Finance
Today's Analyst Rating Update on Incyte (INCY): Evercore ISI Gro - GuruFocus
Incyte Corporation $INCY Shares Bought by Victory Capital Management Inc. - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Teachers Retirement System of The State of Kentucky Has $30.18 Million Stake in Incyte Corporation $INCY - MarketBeat
INCY Earnings History & Surprises | EPS & Revenue Results | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi By Investing.com - Investing.com Canada
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi - Investing.com
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
TD Asset Management Inc Increases Position in Incyte Corporation $INCY - MarketBeat
Incyte to Present at Three March Investor Conferences - MyChesCo
Incyte (INCY) Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential - simplywall.st
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Lilly and Incyte’s Olumiant Recommended in EU for Adolescents with Severe Alopecia Areata - Contract Pharma
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Andra AP fonden Boosts Stake in Incyte Corporation $INCY - MarketBeat
NICE backs approval for Incyte’s Opzelura - The Pharma Letter
Incyte Earnings Underscore Shift From Jakafi Reliance To Broader Pipeline - Yahoo Finance
INCYTE (INCY) R&D president exercises options, sells 18,668 shares at $100.91 - Stock Titan
Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals - ChartMill
Incyte Stock Fell 7% Last Week. Here’s What the Rest of 2026 Could Look Like - TIKR.com
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales - Finviz
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.67%
자본화:
|
볼륨(24시간):